Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention

Dirk Sibbing, Daniel Aradi, Dimitrios Alexopoulos, Jurrien ten Berg, Deepak L. Bhatt, Laurent Bonello, Jean Philippe Collet, Thomas Cuisset, Francesco Franchi, Lisa Gross, Paul Gurbel, Young Hoon Jeong, Roxana Mehran, David J. Moliterno, Franz Josef Neumann, Naveen L. Pereira, Matthew J. Price, Marc S. Sabatine, Derek Y.F. So, Gregg W. StoneRobert F. Storey, U. Tantry, Dietmar Trenk, M. Valgimigli, Ron Waksman, Dominick J. Angiolillo

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary intervention. The availability of different P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or de-escalation of P2Y12-inhibiting therapy. Indeed, individualized and alternative DAPT strategies may be chosen according to the clinical setting (stable coronary artery disease vs. acute coronary syndrome), the stage of the disease (early- vs. long-term treatment), and patient risk for ischemic and bleeding complications. A tailored DAPT approach may be potentially guided by platelet function testing (PFT) or genetic testing. Although the routine use of PFT or genetic testing in percutaneous coronary intervention–treated patients is not recommended, recent data have led to an update in guideline recommendations that allow considering selective use of PFT for DAPT de-escalation. However, guidelines do not expand on when to implement the selective use of such assays into decision making for personalized treatment approaches. Therefore, an international expert consensus group of key leaders from North America, Asia, and Europe with expertise in the field of antiplatelet treatment was convened. This document updates 2 prior consensus papers on this topic and summarizes the contemporary updated expert consensus recommendations for the selective use of PFT or genotyping in patients undergoing percutaneous coronary intervention.

Original languageEnglish (US)
Pages (from-to)1521-1537
Number of pages17
JournalJACC: Cardiovascular Interventions
Volume12
Issue number16
DOIs
StatePublished - Aug 26 2019

Fingerprint

Genetic Testing
Percutaneous Coronary Intervention
Consensus
Blood Platelets
Therapeutics
clopidogrel
Northern Asia
Guidelines
Acute Coronary Syndrome
North America
Aspirin
Coronary Artery Disease
Decision Making
Hemorrhage
Physicians

Keywords

  • genotyping
  • P2Y receptor inhibitor
  • platelet function testing
  • thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. / Sibbing, Dirk; Aradi, Daniel; Alexopoulos, Dimitrios; ten Berg, Jurrien; Bhatt, Deepak L.; Bonello, Laurent; Collet, Jean Philippe; Cuisset, Thomas; Franchi, Francesco; Gross, Lisa; Gurbel, Paul; Jeong, Young Hoon; Mehran, Roxana; Moliterno, David J.; Neumann, Franz Josef; Pereira, Naveen L.; Price, Matthew J.; Sabatine, Marc S.; So, Derek Y.F.; Stone, Gregg W.; Storey, Robert F.; Tantry, U.; Trenk, Dietmar; Valgimigli, M.; Waksman, Ron; Angiolillo, Dominick J.

In: JACC: Cardiovascular Interventions, Vol. 12, No. 16, 26.08.2019, p. 1521-1537.

Research output: Contribution to journalReview article

Sibbing, D, Aradi, D, Alexopoulos, D, ten Berg, J, Bhatt, DL, Bonello, L, Collet, JP, Cuisset, T, Franchi, F, Gross, L, Gurbel, P, Jeong, YH, Mehran, R, Moliterno, DJ, Neumann, FJ, Pereira, NL, Price, MJ, Sabatine, MS, So, DYF, Stone, GW, Storey, RF, Tantry, U, Trenk, D, Valgimigli, M, Waksman, R & Angiolillo, DJ 2019, 'Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention', JACC: Cardiovascular Interventions, vol. 12, no. 16, pp. 1521-1537. https://doi.org/10.1016/j.jcin.2019.03.034
Sibbing, Dirk ; Aradi, Daniel ; Alexopoulos, Dimitrios ; ten Berg, Jurrien ; Bhatt, Deepak L. ; Bonello, Laurent ; Collet, Jean Philippe ; Cuisset, Thomas ; Franchi, Francesco ; Gross, Lisa ; Gurbel, Paul ; Jeong, Young Hoon ; Mehran, Roxana ; Moliterno, David J. ; Neumann, Franz Josef ; Pereira, Naveen L. ; Price, Matthew J. ; Sabatine, Marc S. ; So, Derek Y.F. ; Stone, Gregg W. ; Storey, Robert F. ; Tantry, U. ; Trenk, Dietmar ; Valgimigli, M. ; Waksman, Ron ; Angiolillo, Dominick J. / Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. In: JACC: Cardiovascular Interventions. 2019 ; Vol. 12, No. 16. pp. 1521-1537.
@article{e1c5c9b64be94cd593ba2c12dedbcd8c,
title = "Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention",
abstract = "Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary intervention. The availability of different P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or de-escalation of P2Y12-inhibiting therapy. Indeed, individualized and alternative DAPT strategies may be chosen according to the clinical setting (stable coronary artery disease vs. acute coronary syndrome), the stage of the disease (early- vs. long-term treatment), and patient risk for ischemic and bleeding complications. A tailored DAPT approach may be potentially guided by platelet function testing (PFT) or genetic testing. Although the routine use of PFT or genetic testing in percutaneous coronary intervention–treated patients is not recommended, recent data have led to an update in guideline recommendations that allow considering selective use of PFT for DAPT de-escalation. However, guidelines do not expand on when to implement the selective use of such assays into decision making for personalized treatment approaches. Therefore, an international expert consensus group of key leaders from North America, Asia, and Europe with expertise in the field of antiplatelet treatment was convened. This document updates 2 prior consensus papers on this topic and summarizes the contemporary updated expert consensus recommendations for the selective use of PFT or genotyping in patients undergoing percutaneous coronary intervention.",
keywords = "genotyping, P2Y receptor inhibitor, platelet function testing, thrombosis",
author = "Dirk Sibbing and Daniel Aradi and Dimitrios Alexopoulos and {ten Berg}, Jurrien and Bhatt, {Deepak L.} and Laurent Bonello and Collet, {Jean Philippe} and Thomas Cuisset and Francesco Franchi and Lisa Gross and Paul Gurbel and Jeong, {Young Hoon} and Roxana Mehran and Moliterno, {David J.} and Neumann, {Franz Josef} and Pereira, {Naveen L.} and Price, {Matthew J.} and Sabatine, {Marc S.} and So, {Derek Y.F.} and Stone, {Gregg W.} and Storey, {Robert F.} and U. Tantry and Dietmar Trenk and M. Valgimigli and Ron Waksman and Angiolillo, {Dominick J.}",
year = "2019",
month = "8",
day = "26",
doi = "10.1016/j.jcin.2019.03.034",
language = "English (US)",
volume = "12",
pages = "1521--1537",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "16",

}

TY - JOUR

T1 - Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention

AU - Sibbing, Dirk

AU - Aradi, Daniel

AU - Alexopoulos, Dimitrios

AU - ten Berg, Jurrien

AU - Bhatt, Deepak L.

AU - Bonello, Laurent

AU - Collet, Jean Philippe

AU - Cuisset, Thomas

AU - Franchi, Francesco

AU - Gross, Lisa

AU - Gurbel, Paul

AU - Jeong, Young Hoon

AU - Mehran, Roxana

AU - Moliterno, David J.

AU - Neumann, Franz Josef

AU - Pereira, Naveen L.

AU - Price, Matthew J.

AU - Sabatine, Marc S.

AU - So, Derek Y.F.

AU - Stone, Gregg W.

AU - Storey, Robert F.

AU - Tantry, U.

AU - Trenk, Dietmar

AU - Valgimigli, M.

AU - Waksman, Ron

AU - Angiolillo, Dominick J.

PY - 2019/8/26

Y1 - 2019/8/26

N2 - Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary intervention. The availability of different P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or de-escalation of P2Y12-inhibiting therapy. Indeed, individualized and alternative DAPT strategies may be chosen according to the clinical setting (stable coronary artery disease vs. acute coronary syndrome), the stage of the disease (early- vs. long-term treatment), and patient risk for ischemic and bleeding complications. A tailored DAPT approach may be potentially guided by platelet function testing (PFT) or genetic testing. Although the routine use of PFT or genetic testing in percutaneous coronary intervention–treated patients is not recommended, recent data have led to an update in guideline recommendations that allow considering selective use of PFT for DAPT de-escalation. However, guidelines do not expand on when to implement the selective use of such assays into decision making for personalized treatment approaches. Therefore, an international expert consensus group of key leaders from North America, Asia, and Europe with expertise in the field of antiplatelet treatment was convened. This document updates 2 prior consensus papers on this topic and summarizes the contemporary updated expert consensus recommendations for the selective use of PFT or genotyping in patients undergoing percutaneous coronary intervention.

AB - Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary intervention. The availability of different P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or de-escalation of P2Y12-inhibiting therapy. Indeed, individualized and alternative DAPT strategies may be chosen according to the clinical setting (stable coronary artery disease vs. acute coronary syndrome), the stage of the disease (early- vs. long-term treatment), and patient risk for ischemic and bleeding complications. A tailored DAPT approach may be potentially guided by platelet function testing (PFT) or genetic testing. Although the routine use of PFT or genetic testing in percutaneous coronary intervention–treated patients is not recommended, recent data have led to an update in guideline recommendations that allow considering selective use of PFT for DAPT de-escalation. However, guidelines do not expand on when to implement the selective use of such assays into decision making for personalized treatment approaches. Therefore, an international expert consensus group of key leaders from North America, Asia, and Europe with expertise in the field of antiplatelet treatment was convened. This document updates 2 prior consensus papers on this topic and summarizes the contemporary updated expert consensus recommendations for the selective use of PFT or genotyping in patients undergoing percutaneous coronary intervention.

KW - genotyping

KW - P2Y receptor inhibitor

KW - platelet function testing

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85064718805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064718805&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2019.03.034

DO - 10.1016/j.jcin.2019.03.034

M3 - Review article

C2 - 31202949

AN - SCOPUS:85064718805

VL - 12

SP - 1521

EP - 1537

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 16

ER -